The Clinical Chemist

Morton K. Schwartz, PhD, FACB, is attending clinical chemist, chairman of the department of clinical laboratories, and head of the laboratory of applied and diagnostic biochemistry at Memorial Sloan Kettering Cancer Center in New York City. He has served as president of AACC, as president of the National Registry in Clinical Chemistry, as chairman of the Food and Drug Administration Clinical Chemistry and Hematology Panel, as a member of the National Cancer Institute immunodiagnosis study section and of numerous National Institutes of Health ad hoc study sections, as secretary of the National Committee on Health Laboratory Services, as secretary of the Committee of Scientific Society Presidents, as a member of the executive committee of the Academy of Clinical Laboratory Physicians and Scientists, as a member of the board of directors of the Board of the Registry of the American Society for Clinical Pathology, as chair of the 1973 and 1983 AACC annual meetings, and as chair of the AACC’s New York Metropolitan Section on two occasions. He has also served on the board of editors of numerous publications. Dr. Schwartz is the author or co-author of more 385 articles and has been co-editor of Advances in Clinical Chemistry and editor of a series of books on clinical and biochemical analysis. Morton K. Schwartz His early research interests in evaluation of metabolic abnormalities after cancer surgery led to the development of nutritional and pharmacologic treatment of gastrectomy and intestinal resection malabsorption. For the past 30 years he has been deeply involved in studies of tumor markers and their use in predicting prognosis and in monitoring patients with cancer. Frank Sedor, PhD, DABCC, FACB, is administrative director of the core, blood gas, and clinical pediatric laboratories as well as director for clinical chemistry, therapeutic drug monitoring, and toxicology services at Duke University Medical Center (Durham, NC). He is also a faculty member in the department of pathology at Duke University. He has held numerous positions within the AACC at the local and national levels, including serving as president in 2000. Dr. Sedor was co-chair of the 1991 and chair of the 1997 annual meeting organizing committees. He has chaired the AACC Council, the Commission on Education and Scientific Affairs, the Meetings Management Group, the Divisions Management Group, the AACC Research Committee, and the Program Coordinating Committee. In the North Carolina Section, he has held every office, including secretary-treasurer, program chair, chair, and councilor at large to the AACC Council. Frank Sedor Dr. Sedor continues his efforts in teaching and research in the areas of laboratory utilization and pediatric and maternal diagnostic tools; he also serves as director of the post-doctoral training program at Duke University Medical Center. He has served as president of the American Board of Clinical Chemistry and on the board of the National Academy of Clinical Biochemistry. He has also served as an invited reviewer for the journals Clinical Chemistry, Archives of Pathology and Laboratory Medicine, American Heart Journal, and Intensive Care Journal. Paul Wolf, MD, is professor of clinical pathology at the University of California, San Diego, where he has served since 1974 with a major emphasis on teaching clinical chemistry and hematopathology. He has been director of clinical laboratories at various academic medical centers, including Stanford University. Dr. Wolf’s main professional achievement has been the teaching of clinical chemistry and hematopathology to medical students, clinical chemists, medical technologists, and pathology residents, with an emphasis on a broad perspective of the disease process with respect to clinical laboratory data. He has received many teaching awards from the senior medical students and faculty at Stanford University and the University of California, San Diego. An AACC member for more than 30 years, he has given numerous workshops and roundtables at AACC annual meetings and at foreign clinical chemistry conferences. He also has received numerous national outstanding speaker awards from the AACC, as well as the outstanding speaker award from the Southern California Section in 1997. Paul Wolf Ishwarlal Jialal, MD, PhD, DABCC, FACB, is the Robert E. Stowell Endowed Chair in Experimental Pathology, director of the laboratory for atherosclerosis and metabolic research, and professor of pathology and internal medicine at the University of California, Davis Medical Center. He is internationally recognized for his research, which has focused on free radical biology and antioxidants in disease, lipid biochemistry and atherosclerosis, diabetic macrovascular disease, and inflammation. Ishwarlal Jialal Dr. Jialal’s scientific expertise has been recognized through appointments to several editorial boards, including Clinical Chemistry, American Journal of Clinical Pathology, Journal of Diabetes and Its Complications, and Atherosclerosis. He has published more than 285 original papers and invited reviews in the areas of clinical biochemistry, atherosclerosis, metabolism, and free radical biology. He has received numerous awards for his work, including the American Heart Association Young Investigator Award, VERIS Award for Nutrition Research, Centrum Center Nutrition Science Award, Outstanding Clinical Chemist Award from the Texas Section of the AACC, International Hermes Prize for Vitamin Research, Bennie Zak Award for Outstanding Research from the AACC’s Lipids and Lipoproteins Division, Grace Goldsmith Award from the American College of Nutrition, and Distinguished Scientist Award from the National Academy of Clinical Biochemistry. George Yousef, MD, PhD, FACB, is a resident in the department of laboratory medicine at Memorial University in St. John’s, Newfoundland, Canada. He received his MD degree from Zagazig University in Egypt and his PhD degree in clinical biochemistry from the University of Toronto in Canada. His research focuses on the role of the kallikrein gene family as cancer markers. In the past few years, he has identified seven new members of the human kallikrein gene family and established the first detailed map of the kallikrein gene locus. His most recent work provides strong evidence suggesting the possible role of kallikreins as serum and tissue markers for endocrine malignancies. He has also cloned three new siglec genes and established a detailed map for the siglec gene locus on chromosome 19. His research has led to the publication of more than 55 papers, and he has written 7 review articles on the human kallikrein gene family. He has contributed numerous GenBank submissions, has five patent applications, and has written two book chapters. George Yousef Amitava Dasgupta, PhD, DABCC, FACB, is professor of pathology and laboratory medicine at the University of Texas Medical School at Houston. He is also the director of the clinical chemistry and toxicology laboratories at Memorial-Hermann Hospital, the medical school’s teaching hospital. His research interest is in the field of therapeutic drug monitoring. He has published many papers on digoxin-like immunoreactive factors (DLIF), increased free (unbound) drug concentrations in uremia, and drug–drug interactions that lead to unexpected concentrations of free drugs. More recently, his interest has focused on the study of complementary and alternative medicines and their effects on abnormal laboratory test results. Amitava Dasgupta Dr. Dasgupta has published 139 papers in peer-reviewed journals along with more than 100 abstracts, invited reviews, and book chapters. He has presented roundtables at every AACC annual meeting since 1995 and presented mini-workshops at several meetings. He has actively promoted the practice of therapeutic drug monitoring in his native India. Since 1998, he has delivered talks at several medical colleges, including the All India Institute of Medical Sciences in New Delhi. He was an invited speaker at the 9th Asian Pacific Congress in Clinical Biochemistry in New Delhi. He plans more lecture tours this year and in years to come to promote the practice of clinical chemistry and toxicology in India. J. Craig Venter, PhD, is the president of three newly formed organizations: The Institute for Genomic Research (TIGR) Center for the Advancement of Genomics, the Institute for Biological Energy Alternatives, and the J. Craig Venter Science Foundation. He has played a leading role in sequencing and analyzing the human genome. In 1992 he founded TIGR, where his team decoded the genome of the first free-living organism. This work was based on a concept using expressed sequence tags that he developed while working at the National Institute of Neurological Disorders and Stroke. In 1998 he founded Celera Genomics. There his work, which featured his “shotgun sequencing” technique to accelerate sequencing, new mathematical algorithms, and automated DNA sequencing machines, culminated in the publication of the human genome in the journal Science in 2001. He has published more than 225 research articles and is among the most frequently cited scientists in biology and medicine. J. Craig Venter Elaine Weidenhammer, PhD, is associate director of corporate development at Nanogen (San Diego, CA), a biotechnology company that develops electronic microarrays for use in clinical diagnostics. She joined Nanogen as a research scientist in 1998 and spent the next 4 years developing gene expression and genotyping applications on the NanoChip microarray. She was involved in the development of novel methodologies for analyzing concentrations of multiple mRNA transcripts over multiple time points on a single microarray. This work produced a recently granted patent, in addition to the winning article, “Multiplexed, Targeted Gene Expression Profiling and Genetic Analysis on Electronic Microarrays”. Her co-authors were Brenda F. Kahl, Ling Wang, Larry Wang, Melanie Duchon, Jo Ann Jackson, Matthew Slater, and Xiao Xu. Elaine Weidenhammer Dr. Weidenhammer recently made the transition from research and development to corporate development at Nanogen. In this role, she provides technical expertise for guiding Nanogen’s strategic development efforts, coordinates external research collaborations, and presents Nanogen’s technology at various workshops and scientific meetings. She is active in the San Diego chapter of the Association for Women in Science, serving as chapter president for 3 years and co-chairing the organizing committee for the chapter’s Women in Bioscience Conference, a biannual event that draws more than 350 people. Mary Lou Gantzer, PhD, is the director of clinical and scientific affairs in the Chemistry/Immunochemistry Group of Dade Behring (Newark, DE). She has served the AACC in a variety of capacities in local sections, in divisions, and at the national level. As a member of the House of Delegates, she served on the Long-Range Planning Committee for 5 years, including 2 years as the chair. She served on the 1992, 1996, and 1998 annual meeting organizing committees (chair of the committee in 1998), on the editorial board of Clinical Laboratory News, and as chair of the Membership Committee. Her highly successful tenure as president was marked by a particular focus on addressing the shortage of clinical laboratory personnel. She continues to serve the Association currently as past president, as a member of the Finance Committee, as a member of the executive committee of the board of directors, and as a member of the program coordinating commission. Mary Lou Gantzer Outside of AACC, Dr. Gantzer is a member of the Society of Chest Pain Centers and Providers, a member of the National Committee for Clinical Laboratory Standards Subcommittee on Outcomes Research, and a member of the National Association of Female Executives. Olé Siggaard-Andersen, MD, PhD, is professor of clinical biochemistry at the University of Copenhagen in Denmark and is a former chair of the department of clinical biochemistry at Herlev University Hospital. His impact began in 1963 with the publication of his doctoral thesis, entitled “The Acid-Base Status of the Blood”, which appeared in five editions and five languages. The book included the “curve nomogram” and the “alignment nomogram”. The curve nomogram was used all over the world in connection with the Astrup method for determination of blood carbon dioxide tension. The method and the nomograms were incorporated in pH-blood gas equipment from Radiometer, Inc. The curve nomogram was reproduced in many textbooks of physiology and clinical chemistry, and the alignment nomogram was reproduced in the Geigy Scientific Tables. Olé Siggaard-Andersen Fifteen years later, Dr. Siggaard-Andersen published a revision of his work he named the Van Slyke equation, which became widely known and was included in the software of many manufacturers of pH-blood gas equipment. His method for anaerobic collection of capillary blood with use of a small piece of iron wire and an external magnet for stirring the blood in the completely filled and closed capillary tube was adopted by all manufacturers of pH-blood gas equipment. More recently, he has been working on a mathematical model of the hemoglobin oxygen dissociation curve, the “tanh equation”, which is based on a hyperbolic tangent function, and on an oxygen status algorithm, a computer program for calculating and displaying pH and blood gas data. Through his long career, Dr. Siggaard-Andersen has served the field in many capacities, working with professional societies and journals.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.